You are here

  • Home
  • Archive
  • Volume 32, Issue Suppl 2
  • 2022-RA-466-ESGO Long-term responders (LTR) to rucaparib in recurrent ovarian cancer: a sub-group analysis from the rucaparib access (RAP) program in Spain by GEICO

Article metrics

Article menu

Download PDFPDF

Ovarian cancer
2022-RA-466-ESGO Long-term responders (LTR) to rucaparib in recurrent ovarian cancer: a sub-group analysis from the rucaparib access (RAP) program in Spain by GEICO
Free

 

Online download statistics by month:

Online download statistics by month: October 2022 to April 2024

AbstractFullPdf
Oct 20221003
Nov 202246011
Dec 20224807
Jan 20234206
Feb 20231904
Mar 20232005
Apr 20234105
May 20233406
Jun 20232201
Jul 20232005
Aug 20231603
Sep 2023702
Oct 20231403
Nov 20231902
Dec 2023703
Jan 20241901
Feb 2024801
Mar 202412014
Apr 20241803
Total422085